Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib dose-escalation of BEZ235 or BKM120 with weekly paclitaxel with or without trastuzumab
NL-OMON34229Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dactolisib, buparlisib, paclitaxel and trastuzumab in Nonhematologic neoplasms and breast cancer (4 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Maximum tolerated dose of BEZ235 + paclitaxel and 3 more. Started Jul 2011; status: recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on NL-OMON34229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34229.